Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment
Article Figures & Tables
Figures
- Figure 1—
24-h plasma glucose profiles for the five groups on day 7. - -⋄- -, placebo group; —▪—, GLP-1 4 ng · kg–1 · min–1 16-h group; —▴—, GLP-1 8 ng · kg–1 · min–1 16-h group; —⧫—, GLP-1 4 ng · kg–1 · min–1 24-h group; —×—, GLP-1 8 ng · kg–1 · min–1 24-h group.
- Figure 2—
The left column shows the 24-h plasma glucose profiles on day 0 (□) and on day 7 (▪) for the placebo group and the four active treatment regimens. The curves in the center column represent the corresponding insulin profiles and the curves in the right column represent the glucagon profiles. The bars are SEM.
Tables
- Table 1—
Patient characteristics at baseline
Characteristics Placebo group GLP-1 4 ng · kg–1 · min–1 16-h group GLP-1 8 ng · kg–1 · min–1 16-h group GLP-1 4 ng · kg–1 · min–1 24-h group GLP-1 8 ng · kg–1 · min–1 24-h group n 8 8 8 8 8 Female/male (n) 1/7 2/6 5/3 3/5 4/4 Age range (years) 37–69 43–62 42–66 50–67 52–68 Weight range (kg) 61–99 67–110 68–108 62–99 75–117 Height range (cm) 163–183 157–180 147–180 148–178 155–183 HbA1c (%) 9.8 ± 2.6 9.9 ± 1.9 9.5 ± 2.3 8.8 ± 2.2 10.1 ± 1.4 FPG (mmol/l) 12.7 ± 1.7 13.5 ± 2.5 14.2 ± 4.1 12.5 ± 3.7 15.9 ± 4.2 -
Data are means ± SD unless otherwise indicated.
-
- Table 2—
24-h mean values and changes from baseline for glucose, insulin, and glucagons
Placebo group GLP-1 4 ng · kg–1 · min–1 16-h group GLP-1 8 ng · kg–1 · min–1 16-h group GLP-1 4 ng · kg–1 · min–1 24-h group GLP-1 8 ng · kg–1 · min–1 24-h group Glucose (mmol/l) Baseline 15.3 15.2 14.8 17.2 18.3 Change (day 1) −0.2 −3.2* −4.4* −4.7* −6.6*† Change (day 4) +1.1 −3.4* −3.7* −4.6* −10.9*† Change (day 7) +1.3 −3.9* −4.7* −5.2* −7.7*† Insulin (μU/ml) Baseline 37 54 49 36 30 Change −3 +3 −5 −7 −7 Glucagon (pg/ml) Baseline 84 107 118 115 114 Change +6 −7 −30‡ −24‡ −30‡ - Table 3—
Overall AE with a rate of occurrence in two or more patients
Placebo group GLP-1 4 ng · kg–1 · min–1 16-h group GLP-1 8 ng · kg–1 · min–1 16-h group GLP-1 4 ng · kg–1 · min–1 24-h group GLP-1 8 ng · kg–1 · min–1 24-h group Patients with at least one event 6 5 7 4 7 Total number of unique events 14 14 21 7 29 Cellulitis 2 0 0 1 2 Fever 1 1 0 0 2 Chills 0 1 0 0 1 Headache 3 2 2 2 3 Injection site reaction 2 0 0 0 2 Abdominal pain 2 2 2 0 1 Back pain 0 0 1 0 3 Diarrhea 0 0 1 0 1 Dyspepsia 0 0 3 2 2 Nausea 1 2 4 0 4 Vomiting 1 2 3 1 3 Dizziness 0 1 3 0 1 Tremor 0 1 0 0 1 -
Data are n.
-
In this Issue
